$NEU large move, base, need to form RS (tighten) ready for B/O$NEU large move, base, need to form RS (tighten) ready for B/O
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.11 AUD
142.04 M AUD
213.24 M AUD
109.19 M
About NEUREN PHARMACEUTICALS LIMITED
Sector
Industry
CEO
Jonathan Charles Pilcher
Website
Headquarters
Camberwell
Founded
2004
ISIN
NZNEUE0001S8
FIGI
BBG000CS0GB6
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
Neuren Had A Classical Minervini / Upper Bollinger Breakout RunAnother great mover on todays Australian Stock Exchange.
Classic Bollinger breakout after a long sideways squeeze and volume coming through as well.
NEU 6 month breakout 1.48 and good buying up this week. $NEU Neuren Pharmaceutical with good buying this week. Not much news out, but investor presentation this week. 6 month breakout $1.48. Strong support 1.25 Some director buying around 1.40. MC $170m SOI 115m. $neu.ax
NEU waiting game, Patience, patience ...NEU holding support at 2.89 very nicely, a lot of accumulation, a matter of time before this one start running
NEU Great fundamental/all indicators in the greenNEU double bottomed after double toped, show consolidation, Downtrend breakout and MACD turning green showing sign of moving opposite direction.
1st Price target of 3.50 short Term ( 14% ) , if break through 6.45 could become the next target .
$NEU trendline break post recent consolidationFirst consolidation post consolidation. moving through trendline, see if it can re-test old highs.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of NEU is 11.34 AUD — it has increased by 3.00% in the past 24 hours. Watch NEUREN PHARMACEUTICALS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange NEUREN PHARMACEUTICALS LIMITED stocks are traded under the ticker NEU.
NEU stock has risen by 12.17% compared to the previous week, the month change is a −9.06% fall, over the last year NEUREN PHARMACEUTICALS LIMITED has showed a −41.24% decrease.
We've gathered analysts' opinions on NEUREN PHARMACEUTICALS LIMITED future price: according to them, NEU price has a max estimate of 30.80 AUD and a min estimate of 20.00 AUD. Watch NEU chart and read a more detailed NEUREN PHARMACEUTICALS LIMITED stock forecast: see what analysts think of NEUREN PHARMACEUTICALS LIMITED and suggest that you do with its stocks.
NEU stock is 5.20% volatile and has beta coefficient of 2.42. Track NEUREN PHARMACEUTICALS LIMITED stock price on the chart and check out the list of the most volatile stocks — is NEUREN PHARMACEUTICALS LIMITED there?
Today NEUREN PHARMACEUTICALS LIMITED has the market capitalization of 1.43 B, it has increased by 14.58% over the last week.
Yes, you can track NEUREN PHARMACEUTICALS LIMITED financials in yearly and quarterly reports right on TradingView.
NEUREN PHARMACEUTICALS LIMITED is going to release the next earnings report on Aug 26, 2025. Keep track of upcoming events with our Earnings Calendar.
NEU earnings for the last half-year are 1.02 AUD per share, whereas the estimation was 1.04 AUD, resulting in a −1.30% surprise. The estimated earnings for the next half-year are 0.073 AUD per share. See more details about NEUREN PHARMACEUTICALS LIMITED earnings.
NEUREN PHARMACEUTICALS LIMITED revenue for the last half-year amounts to 191.54 M AUD, despite the estimated figure of 184.11 M AUD. In the next half-year revenue is expected to reach 30.42 M AUD.
NEU net income for the last half-year is 134.03 M AUD, while the previous report showed 8.02 M AUD of net income which accounts for 1.57 K% change. Track more NEUREN PHARMACEUTICALS LIMITED financial stats to get the full picture.
No, NEU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEUREN PHARMACEUTICALS LIMITED EBITDA is 175.59 M AUD, and current EBITDA margin is 82.34%. See more stats in NEUREN PHARMACEUTICALS LIMITED financial statements.
Like other stocks, NEU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEUREN PHARMACEUTICALS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEUREN PHARMACEUTICALS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEUREN PHARMACEUTICALS LIMITED stock shows the sell signal. See more of NEUREN PHARMACEUTICALS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.